Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1	Cyclo Therapeutics, Inc	Ongoing	Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™)	3	CTD-TCNPC-301	King Faisal Specialist Hospital and Research Center (Riyadh)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study	King Abdullah International Medical Research Center (KAIMRC)	Rejected	BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine	2	RJ19/119/J	King Abdulaziz Medical City NG (Jeddah)
REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line.	Bayer Saudi Arabia LLC	Ongoing	ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib,	4	22453	King Faisal Specialist Hospital and Research Center (Jeddah)
A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia	Sanofi	Ongoing	iGlarLixi	4	OBS17984	King Fahad Medical City (Riyadh),King Fahad Specialist Hospital, Buraydah, Hira Hospital (Makkah) ,Al-AlSheikh Diabetes Cente (Riyadh)
PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING BLEEDING INCIDENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS AND NON-INHIBITORS TREATED WITH EMICIZUMAB AND OTHER HEMOPHILIA TREATMENTS IN A REAL-LIFE SETTING	Roche	Ongoing	emicizumab	4	MO401001	King Abdulaziz Medical City NG (Jeddah)
A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice	NovoNordisk	Ongoing	Sogroya®	4	NN8640-451	My Clinic (Jeddah),King Fahad Medical City (Riyadh),Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh)
Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)	King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia	Ongoing	WARFARIN SODIUM	3	2231351	King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, Single Oral Dose, Open Label, Two Sequence, Two Treatment, Four Periods, Full Replicate Crossover Study to Determine the Bioequivalence of Azacitidine 300 mg Film Coated Tablets Versus Onureg® 300 mg Film Coated Tablets For Adult Patients with Acute Myeloid Leukaemia (AML) under Fasting Conditions	Hikma Pharmaceuticals	Ongoing	Azacitidine 300 mg Film- Coated Tablets	BE	HIK-AZA-2023-01	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease	Vertex Pharmaceuticals	Ongoing	Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001)	3	VX21-CTX001-161	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD	Boehringer	Ongoing	BI 456906	3	1404-0040	King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah),King Saud Medical City (Riyadh)